ArticleBMC infectious diseases2026
Relapse of HIV-associated multicentric Castleman disease temporally associated with acute coronavirus disease 2019: a case report.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman immunodeficiency virus-associated multicentric Castleman disease (HIV-MCD), a human herpesvirus 8 (HHV-8)-driven lymphoproliferative disorder affecting individuals infected by HIV, typically exhibits a relapsing-remitting course and can be fatal. The incidence of HIV-MCD is on the rise while that of Kaposi's sarcoma, another HHV-8-associated disease, has been declining. Although an increasing number of studies have reported relapses of human herpesvirus-associated diseases and HIV-negative MCD following coronavirus disease 2019 (COVID-19), to the best of our knowledge there are no reports of HIV-MCD relapses. CASE PRESENTATION: A 75-year-old male patient with well-controlled HIV infection and pre-existing HIV-MCD experienced a relapse of HIV-MCD temporally associated with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). He had a two-month history of persistent cough and received the diagnosis of mild COVID-19 based on positivity for SARS-CoV-2 on a polymerase chain reaction test and characteristic findings on computed tomography. Although the COVID-19 resolved with remdesivir therapy, the patient subsequently experienced a fever, generalized lymphadenopathy, splenomegaly, and thrombocytopenia. A lymph node biopsy confirmed a MCD relapse. The patient improved markedly after rituximab therapy.
conclusionThis case is the first to report a temporal association between SARS-CoV-2 infection and HIV-MCD relapse. While a direct causal relationship cannot be established, the clinical course is consistent with the hypothesis that SARS-CoV-2 infection may have contributed to HHV-8 reactivation and MCD relapse. Further case series and mechanistic studies are needed to evaluate this potential association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.